



The Illinois Medical Bulletin



The Impact of Targeting KIT Mutations with Imatinib in Gastrointestinal Stromal Tumors: A Review of a Therapeutic Revolution

¹A. Cahill, ²A. Carranza

^{1,2} University of Illinois College of Medicine

Corresponding Email : cahillmd938447@gmail.com

Article History :

Received date : 2018/10/12
Revised date : 2018/11/28
Accepted date : 2018/12/09
Published date : 2019/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: Gastrointestinal Stromal Tumors (GISTs) are rare mesenchymal tumors that were historically highly resistant to conventional chemotherapy, resulting in a poor prognosis for patients with advanced disease. A fundamental breakthrough was the discovery that most GISTs are driven by activating mutations in the KIT receptor tyrosine kinase.

Literature Review: A review of the pivotal literature chronicles a rapid and complete paradigm shift in the management of this disease. The discovery of the central role of KIT mutations provided a clear molecular target for the tyrosine kinase inhibitor, imatinib. Initial, groundbreaking clinical trials in patients with metastatic GIST demonstrated unprecedented and dramatic rates of clinical response, with the vast majority of patients achieving either significant tumor shrinkage or durable disease stabilization. Large, randomized phase III trials subsequently confirmed the profound survival benefit of imatinib, extending median survival from less than a year to several years. This success was extended to the curative-intent setting, where a landmark adjuvant trial showed that imatinib therapy after surgery significantly reduced the risk of tumor recurrence in patients with high-risk GIST.

Conclusion: The body of evidence unequivocally established targeted therapy with imatinib as the standard of care for KIT-positive GIST. This research transformed a once untreatable solid tumor into a chronically manageable, and sometimes curable, condition, serving as a quintessential example of the success of molecularly guided cancer therapy.

Keywords: Gastrointestinal Stromal Tumor (GIST), KIT, Imatinib, Targeted Therapy, Tyrosine Kinase Inhibitor.

INTRODUCTION

Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. For many years, they were poorly understood and often misclassified as other types of soft tissue sarcomas. For patients with unresectable or metastatic disease, the prognosis was exceptionally grim. GISTs demonstrated a profound and intrinsic resistance to standard cytotoxic chemotherapy and radiation therapy, leaving patients with virtually no effective systemic treatment options and a median survival of approximately one year.

This dismal outlook was completely transformed by a fundamental discovery in the molecular pathogenesis of the disease. Research identified that the vast majority of GISTs are not driven by random mutations, but by a specific, identifiable oncogenic driver: gain-of-function mutations in the gene encoding the KIT receptor tyrosine kinase. This discovery unlocked a specific molecular vulnerability and paved the way for one of the most successful applications of targeted therapy in the history of oncology. This literature review will synthesise the pivotal clinical trial evidence that established the profound efficacy of the KIT inhibitor, imatinib, in the treatment of GIST.

LITERATURE REVIEW

The revolution in GIST management is a direct result of translating a key molecular insight into a highly effective therapy, a process documented in a series of landmark clinical trials.

The foundational discovery was the identification of activating mutations in the *KIT* proto-oncogene as the defining molecular feature of most GISTs. The KIT protein is a receptor tyrosine kinase that, under normal circumstances, is activated only when its ligand (stem cell factor) is present. The mutations found in GISTs cause the KIT protein to be permanently switched on, leading to constant, uncontrolled signaling that drives cell proliferation and survival. This finding not only reclassified GIST as a distinct entity but also provided an ideal

therapeutic target (Fletcher et al., 2002). Coincidentally, imatinib mesylate, a drug developed to inhibit the BCR-ABL kinase in chronic myeloid leukemia, was also found to be a potent inhibitor of the KIT kinase.

This led to groundbreaking early-phase clinical trials in patients with advanced GIST who had exhausted all other options. The results were immediate, dramatic, and unprecedented for a solid tumor treated with a targeted agent. A pivotal phase II trial demonstrated that imatinib produced objective tumor responses (significant shrinkage) in over half of the patients, with an additional third experiencing disease stabilization. In total, over 80% of patients derived clinical benefit from a well-tolerated oral medication in a disease that was previously considered untreatable (Demetri et al., 2002). A concurrent European trial reported nearly identical, spectacular results, confirming the profound activity of the drug (van Oosterom et al., 2001).

These initial findings were solidified in a large, international, randomized phase III trial. This study confirmed the durable benefit of imatinib and established a new median survival for patients with metastatic GIST that was measured in years, not months, completely altering the natural history of the disease (Blanke et al., 2008). This research also began to uncover nuances, showing that the specific type of *KIT* mutation (e.g., an exon 11 mutation versus an exon 9 mutation) could influence the degree of sensitivity to imatinib, an early insight into genotype-phenotype correlations in targeted therapy.

The remarkable success of imatinib in the advanced setting logically led to its investigation in the adjuvant setting—that is, as a treatment after complete surgical resection of a primary GIST to prevent recurrence. A landmark, randomized, placebo-controlled trial was conducted in patients with high-risk GIST. The results were again positive and practice-changing. The study showed that one year of adjuvant imatinib therapy resulted in a highly significant improvement in recurrence-free survival compared to placebo, establishing a new standard of care aimed at increasing the cure rate for patients with high-risk localized disease (DeMatteo et al., 2009).

CONCLUSION

The pivotal literature on the use of imatinib in Gastrointestinal Stromal Tumors chronicles one of the fastest and most complete therapeutic revolutions in modern oncology. The identification

of activating KIT mutations as the core oncogenic driver provided the perfect molecular target for a rationally designed drug.

The subsequent clinical trials provided unequivocal and dramatic evidence of imatinib's efficacy, first in the metastatic setting, where it transformed a rapidly fatal disease into a manageable chronic condition, and later in the adjuvant setting, where it was shown to prevent disease recurrence. This body of work established targeted inhibition of KIT as the absolute standard of care for GIST and stands as a powerful and enduring paradigm of how a deep understanding of a cancer's molecular pathogenesis can be translated into a highly effective, life-saving therapy.

REFERENCES

Blanke, C.D., Demetri, G.D., von Mehren, M., Heinrich, M.C., Eisenberg, B., Fletcher, J.A., Corless, C.L., Fletcher, C.D., Roberts, P.J., Heinz, D., Wehre, E., Nikolova, Z. and Joensuu, H. (2008) 'Long-term results from a randomized phase II trial of standard- versus high-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors', *Journal of Clinical Oncology*, 26(4), pp. 620-625.

DeMatteo, R.P., Ballman, K.V., Antonescu, C.R., Maki, R.G., Pisters, P.W.T., Demetri, G.D., Blackstein, M.E., Blanke, C.D., von Mehren, M., Brennan, M.F., Patel, S., McCarter, M.D., Polikoff, J.A., Tan, B.R., Owzar, K. and American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. (2009) 'Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial', *The Lancet*, 373(9669), pp. 1097-1104.

Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisenberg, B., Roberts, P.J., Heinrich, M.C., Tuveson, D.A., Singer, S., Janicek, M., Fletcher, J.A., Silverman, S.G., Silberman, S.L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B.J., Corless, C., Fletcher, C.D. and Joensuu, H. (2002) 'Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors', *New England Journal of Medicine*, 347(7), pp. 472-480.

Fletcher, C.D.M., Berman, J.J., Corless, C., Gorstein, F., Lasota, J., Longley, B.J., Miettinen, M., O'Leary, T.J., Remotti, H., Rosai, J., Sobin, L.H., Stulov, I. and Weiss, S.W. (2002) 'Diagnosis of gastrointestinal stromal tumors: a consensus approach', *Human Pathology*, 33(5), pp. 459-465.

van Oosterom, A.T., Judson, I., Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., Silberman, S. and Nielsen, O.S. (2001) 'Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study', *The Lancet*, 358(9291), pp. 1421-1423.